Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA) CEO Dale B. Schenk acquired 8,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average cost of $20.79 per share, with a total value of $166,320.00. Following the transaction, the chief executive officer now directly owns 8,161 shares in the company, valued at approximately $169,667. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

PRTA has been the subject of a number of recent research reports. Analysts at Wedbush upgraded shares of Prothena Co. PLC to a “best ideas list” rating in a research note on Friday, April 25th. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Prothena Co. PLC in a research note on Thursday, April 24th. They now have a $60.00 price target on the stock. Finally, analysts at Citigroup Inc. initiated coverage on shares of Prothena Co. PLC in a research note on Wednesday, April 9th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $43.75.

Prothena Co. PLC (NASDAQ:PRTA) traded up 7.64% on Monday, hitting $20.86. The stock had a trading volume of 295,156 shares. Prothena Co. PLC has a 52-week low of $8.20 and a 52-week high of $49.24. The stock’s 50-day moving average is $30.41 and its 200-day moving average is $29.57. The company’s market cap is $456.9 million. Prothena Co. PLC also saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 763,327 shares, an increase of 41.4% from the April 15th total of 539,731 shares. Based on an average daily volume of 835,091 shares, the short-interest ratio is currently 0.9 days. Approximately 3.5% of the company’s stock are sold short.

Prothena Co. PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.81 by $0.03.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.